Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia

An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants

NCT02535026 ·Status: COMPLETED

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

NCT05217381 ·Status: COMPLETED

Safety, Effectiveness and Quality of Life of Trastuzumab Deruxtecan in Patients with HER2+ Breast Cancer

NCT05149014 ·Status: COMPLETED

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

NCT05367739 ·Status: COMPLETED

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

NCT03451162 ·Status: COMPLETED ·Phase: PHASE1

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

NCT03709082 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

NCT06954961 ·Status: RECRUITING ·Phase: PHASE3

Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast Cancer

NCT06492447 ·Status: NOT_YET_RECRUITING

Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

NCT04937660 ·Status: COMPLETED

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

NCT07002177 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer

NCT02342587 ·Status: COMPLETED ·Phase: PHASE2

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

NCT07187752 ·Status: NOT_YET_RECRUITING ·Phase: NA

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

NCT02980341 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

NCT05599334 ·Status: COMPLETED

Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer

NCT02599714 ·Status: COMPLETED ·Phase: PHASE1

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717 ·Status: RECRUITING ·Phase: PHASE1

B002 in Patients With HER2-positive Breast Cancer

NCT04382352 ·Status: COMPLETED ·Phase: PHASE1

A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

NCT05478590 ·Status: COMPLETED

Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer

NCT02476539 ·Status: COMPLETED ·Phase: PHASE1

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481 ·Status: COMPLETED

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

NCT06544577 ·Status: RECRUITING

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT04851613 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 ·Status: COMPLETED